Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Top Page
Pacira Pharmaceuticals
(NASDAQ:PCRX)
Rating:63Neutral
Price Target:
$27.00
▲( 3.29% Upside)
Positive Factors
NOPAIN Reimbursement
The NOPAIN reimbursement change, which removes Exparel from the surgical bundle and offers additional reimbursement incentives, could impact pricing strategy positively.
Settlement Agreement
A settlement agreement with Fresenius that provides Exparel exclusivity into 2039.
Share Repurchase
A new $300MM share repurchase program has been announced.
Negative Factors
Competitive Pressures
There are concerns about competitive pressures impacting Pacira's market share.
Regulatory Challenges
Regulatory challenges could pose risks to Pacira's upcoming product launches.
Pacira Pharmaceuticals (PCRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.24B
Dividend YieldN/A
Average Volume (3M)1.06M
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue Growth3.08%
EPS Growth-247.82%
CountryUS
Employees788
SectorHealthcare
Sector Strength44
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.62
Shares Outstanding46,304,670
10 Day Avg. Volume1,192,034
30 Day Avg. Volume1,057,502
Financial Highlights & Ratios
PEG Ratio1.20
Price to Book (P/B)1.48
Price to Sales (P/S)0.00
P/FCF Ratio6.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$35.50Price Target Upside35.81% Upside
Rating ConsensusHold
Number of Analyst Covering8
Pacira Pharmaceuticals Business Overview & Revenue Model
Company DescriptionPacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
How the Company Makes MoneyPacira Pharmaceuticals generates revenue primarily through the sale of its products, with EXPAREL being the key driver of its income. The company earns money by selling EXPAREL directly to hospitals, ambulatory surgical centers, and other healthcare facilities. Additionally, Pacira has strategic partnerships and collaborations with other healthcare organizations to expand its market reach and product offerings, which also contribute to its revenue streams. The company's efforts to promote the benefits of non-opioid pain management solutions are critical to its financial success, as they help increase the adoption and utilization of its products.
Pacira Pharmaceuticals Financial Statement Overview
Summary
Pacira Pharmaceuticals exhibits stable revenue growth and strong cash flows, but struggles with profitability and operational efficiency. The balance sheet shows improved leverage but concerns remain over shareholder returns.Income Statement
Pacira Pharmaceuticals has shown a mixed performance in its income statement. Revenue growth has been positive over the years, with a 3.85% increase from 2023 to 2024 and a 1.22% increase from 2022 to 2023. However, profitability metrics have declined sharply, with a negative EBIT and EBITDA margin in 2024, indicating operational challenges. The net profit margin turned negative in 2024, reflecting a significant dip from the previous positive results.55
Neutral
Balance Sheet
The company's balance sheet reveals moderate stability. The debt-to-equity ratio improved from 2023 to 2024, indicating better leverage management. However, the equity ratio remained fairly stable at around 50%. Return on equity took a hit in 2024, turning negative, which is a concern for profitability and shareholder returns.60
Neutral
Cash Flow
Cash flow metrics are relatively strong, with a notable free cash flow growth rate of 28.15% from 2023 to 2024. Operating cash flow to net income ratio improved significantly, suggesting better cash management despite the negative net income. Free cash flow remains robust, providing a buffer against operational downturns.70
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 700.97M | 674.98M | 666.82M | 541.53M | 420.83M | Gross Profit |
| 700.97M | 490.31M | 467.53M | 401.28M | 303.50M | EBIT |
| -73.37M | 87.67M | 60.02M | 131.06M | 46.35M | EBITDA |
| 29.12M | 157.58M | 144.78M | 118.47M | 71.42M | Net Income Common Stockholders |
| -99.56M | 41.95M | 15.91M | 41.98M | 145.52M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 276.77M | 278.58M | 288.65M | 656.41M | 521.66M | Total Assets |
| 1.55B | 1.57B | 1.68B | 2.08B | 1.27B | Total Debt |
| 490.00M | 586.04M | 763.39M | 1.13B | 541.13M | Net Debt |
| 213.22M | 432.75M | 659.25M | 543.27M | 441.17M | Total Liabilities |
| 775.17M | 704.26M | 906.19M | 1.34B | 654.83M | Stockholders Equity |
| 778.35M | 870.13M | 775.01M | 730.41M | 619.69M |
| Cash Flow | Free Cash Flow | |||
| 178.75M | 139.49M | 115.20M | 79.85M | 39.23M | Operating Cash Flow |
| 189.39M | 154.65M | 145.27M | 125.72M | 77.03M | Investing Cash Flow |
| -83.28M | 77.54M | -225.19M | -20.79M | -277.61M | Financing Cash Flow |
| 17.36M | -183.03M | -401.53M | 380.69M | 222.30M |
Pacira Pharmaceuticals Technical Analysis
Positive
26.14
Price Trends
24.93
Positive
24.24
Positive
20.30
Positive
Market Momentum
0.22
Negative
54.52
Neutral
88.82
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCRX, the sentiment is Positive. The current price of 26.14 is above the 20-day moving average (MA) of 25.78, above the 50-day MA of 24.93, and above the 200-day MA of 20.30, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 54.52 is Neutral, neither overbought nor oversold. The STOCH value of 88.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PCRX.
Pacira Pharmaceuticals Risk Analysis
Pacira Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Pacira Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
The patents and the patent applications that we have covering PCRX-201 are limited to composition of matter and uses of an adenoviral vector containing a nucleic acid encoding specific gene and our market opportunity for our product candidate may be limited by the patent protection and other gene therapies for treating OA that may be developed by competitors. Q4, 2024
2.
The patents and the patent applications that we have covering ZILRETTA are limited to specific injectable formulations, uses and processes of manufacturing and our market opportunity for our product candidate may be limited by the lack of patent protection for the active ingredient itself and other formulations and delivery technologies and systems that may be developed by competitors. Q4, 2024
Pacira Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $1.18B | 89.44 | -8.84% | ― | 17.90% | -133.73% | |
63 Neutral | $1.24B | ― | -12.27% | ― | 3.08% | -247.82% | |
53 Neutral | $5.24B | 3.07 | -43.58% | 2.80% | 16.87% | -0.11% | |
51 Neutral | $1.13B | ― | -49.41% | ― | 4.86% | 10.13% | |
50 Neutral | $1.05B | ― | -3.04% | ― | -13.79% | 82.82% | |
48 Neutral | $909.52M | ― | -93.70% | ― | ― | -25.83% | |
39 Underperform | $611.10M | ― | -51.85% | ― | 11070.12% | 32.07% |
* Healthcare Sector Average
Performance Comparison
PCRX
Pacira Pharmaceuticals
26.14
-4.18
-13.79%
OPK
Opko Health
1.30
0.02
1.56%
INVA
Innoviva
18.95
3.16
20.01%
IOVA
Iovance Biotherapeutics
1.76
-8.50
-82.85%
VRDN
Viridian Therapeutics
13.66
1.50
12.34%
SNDX
Syndax Pharmaceuticals
10.65
-9.46
-47.04%
Pacira Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: 4.94%|
Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment with significant strategic wins, including the EXPAREL patent settlement and strong sales growth. However, some challenges remain, particularly in the transition of sales teams and adoption of new reimbursement pathways.Q1-2025 Updates
Positive Updates
EXPAREL Patent Settlement
Successfully settled patent infringement litigation for EXPAREL, extending exclusivity to 2039 and eliminating RDF royalty obligation, benefiting EXPAREL gross margins by a low single-digit percentage.
Growth in EXPAREL Sales
First quarter average daily EXPAREL sales and volumes were up approximately 7% over 2024, after adjusting for two fewer selling days in 2025.
PCRX-201 Progress
Patient dosing underway in Phase 2 ASCEND study of PCRX-201 in osteoarthritis of the knee, with promising early data suggesting potential for long-term pain relief.
Stock Repurchase Program
Announced a $300 million stock repurchase program, doubling the previous authorization, indicating confidence in growth outlook.
Strong Financial Performance
Consolidated first quarter non-GAAP gross margin improved to 81% from 72% last year, driven by improved costs and efficiencies.
Negative Updates
ZILRETTA Sales Decline
First quarter ZILRETTA sales declined to $23.3 million from $25.8 million in 2024 due to the transition to new sales forces.
Challenges in Healthcare Reimbursement
Logistical challenges in hospital systems adopting no pain reimbursement pathways, with broad adoption expected in the second half of the year.
Company Guidance
During the First Quarter 2025 Pacira BioSciences Earnings Conference Call, the company provided substantial guidance reflecting strong growth and strategic initiatives. Pacira introduced its "5x30" path to value creation, aimed at accelerating growth in its commercial business and advancing its innovative pipeline. Key achievements included settling patent litigation for EXPAREL, extending exclusivity to 2039, and reporting a 7% increase in average daily EXPAREL sales and volumes from 2024. The company's non-GAAP gross margin improved to 81%, benefiting from enhanced manufacturing efficiencies. Additionally, Pacira announced a $300 million stock repurchase program, signaling confidence in its growth outlook. The call also highlighted ongoing clinical progress, such as the Phase 2 ASCEND study of PCRX-201 for osteoarthritis, and the strategic acquisition of GQ Bio, enhancing its innovative gene therapy platform. The company's full-year 2025 revenue guidance was reaffirmed at $725 million to $765 million.Pacira Pharmaceuticals Corporate Events
Legal ProceedingsBusiness Operations and Strategy
Pacira Pharmaceuticals Settles Patent Litigation with Fresenius
Neutral
Apr 7, 2025
On April 7, 2025, Pacira BioSciences announced a settlement with Fresenius Kabi and others regarding patent litigations for EXPAREL®, allowing Fresenius to sell limited volumes of a generic version in the U.S. starting in 2030, with unlimited sales permitted from 2039. This agreement resolves ongoing litigations, provides clarity on EXPAREL’s exclusivity, and involves a $7 million payment to Fresenius, potentially impacting Pacira’s market strategy and stakeholder interests.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.